Hepatitis C

With an estimate of as many as 80 million people infected with hepatitis C globally, access to treatment worldwide must be scaled up. To ensure this, the price of oral drugs to treat hepatitis C urgently needs to come down in all developing countries, particularly through competition among generic producers.

18. December 2017.

MSF challenges Gilead’s patent application for hepatitis C in China.

Rejection of patents for this combination would pave the way towards the availability of affordable generic versions of this treatment that millions of people need in China and around the world.

» Read more


Hepatitis C strategies

Hep-C patient being counselled by Psychosocial counsellor at MSF Mumbai clinic on dealing with side effects of the treatment regimen - Photo by Siddharth Singh

Strategies to Secure Access to Generic Hepatitis C Medicines

MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS). Read more

Learn more

Featured multimedia

Hepatitis C: A Call to Action
In September 2012, Médecins Sans Frontières, the Open Society Foundations and Treatment Action Group, joined forces with activists, researchers, UN and government representatives to identify priority issues, share information and develop strategies to overcome the barriers that prevent access to HCV treatment in developing countries, both today and in the future...

Tags: hepatitis c, co-infection

↑ To top